×
Enjoying ad-free content?
Since July 1, 2024, we have disabled all ads to improve your reading experience.
This commitment costs us $10,000 a month. Your support can help us fill the gap.
Support us
Our journalism is banned in Russia. We need your help to keep providing you with the truth.

Russia Approves 2nd Coronavirus Vaccine – Putin

The EpiVacCorona vaccine's approval comes ahead of post-registration trials involving 40,000 volunteers across Russia. Sophia Sandurskaya / Moskva News Agency

Russia has approved its second coronavirus vaccine, President Vladimir Putin announced Wednesday as the peptide-based shot developed by a Siberian biotech company readies for large-scale trials.

“Novosibirsk’s Vektor [State Virology and Biotechnology Center] has registered the second Russian coronavirus vaccine today,” Putin said via televised video conference.

Putin said that Deputy Prime Minister Tatyana Golikova and the head of Russia’s consumer safety watchdog Anna Popova have both received the EpiVacCorona vaccine as part of clinical trials.

Early trials on 100 volunteers were said to have been successful.

Golikova told Putin that post-registration trials of EpiVacCorona will involve 40,000 volunteers across Russia. Vektor plans to produce the first 60,000 doses of EpiVacCorona “in the nearest future,” she added. 

Health officials have so far declined to answer questions about EpiVacCorona’s initial trial results or the approval process, saying that they were reviewing the vaccine for safety and quality.

Golikova added during the video conference that a third candidate coronavirus vaccine will receive government approval sometime in December.

Vektor is a former Soviet bioweapons research lab and, in addition to the U.S. Centers for Disease Control and Prevention, is one of two sites in the world that house smallpox stockpiles. Vektor also houses Ebola samples.

Putin approved Russia’s first Covid-19 vaccine, named Sputnik V in a nod to the Soviet launch of the world's first satellite, on Aug. 11. Sputnik V began large-scale trials on 40,000 volunteers in September. Its developer, the Moscow-based Gamaleya research center, is expected to wrap up the Phase 3 trials sometime around summer 2021.

Russia is the world’s fourth-most affected country by the coronavirus pandemic with a total of 1,340,409 cases. 

It has seen its number of new infections more than double within a month and set single-day records in each of the past six days. On Wednesday, Russia confirmed more than 14,000 new cases for the first time since the start of its outbreak in the spring.

A Message from The Moscow Times:

Dear readers,

We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."

These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.

We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.

By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more